APY29 is a selective inhibitor of PI3K p110α, a key enzyme in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in various cancers. It is primarily used in research settings to study oncogenic signaling and cellular processes such as proliferation, survival, and metabolism. Due to its high selectivity, APY29 allows scientists to dissect the specific role of the p110α isoform in cancer models, making it a valuable tool for validating therapeutic targets. It has also been employed in combination studies with other targeted agents to assess synergistic effects and overcome drug resistance in tumor cells. Its application supports the development of more effective PI3K-targeted therapies in oncology.